Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term changes in pulmonary congestion with intravenous vs oral tolvaptan in heart failure
jRCT1041230150Completed
- Sponsor
- Lidre
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of tolvaptan in heart failure (HF) (2 arms), sponsored by Lidre. Primary endpoints: Rate of change in pulmonary fluid concentration and Rate of improvement in pulmonary congestion by REDS. Started Feb 2024; status: completed.
02
Drugs
tolvaptan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCT1041230150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041230150.